Evaluation of the effectiveness of 10% Dimethyl Sulfoxide gel in the treatment of Macular Amyloidosis: A case series of 30 patients
Keywords:
Macular amyloidosis, Dimethyl sulfoxide, Pruritus, PigmentationAbstract
Introduction: The deposition of various types of proteins in different organs, which can lead to the dysfunction of that organ, is called amyloidosis. Recent studies have focused on the role of dimethyl sulfoxide in the treatment of cutaneous forms of amyloidosis.
Materials and Methods: This descriptive study was conducted on patients who were referred to the dermatology clinic of the Vali-Asr Hospital in Qaemshahr and to private dermatology practices in the city of Sari during a 4-year period, from April 2018 to April 2022. Diagnosis was made based on clinical examinations and precise biopsies by a dermatologist. A 10% dimethyl sulfoxide gel once daily was prescribed for patients. Before the treatment, the lesions were examined by colorimetry, and itching was assessed based on the visual analogue scale (VAS). These were repeated after 24 weeks. Analyses were done using Statistical Package for the Social Sciences (SPSS) version 26.
Results: The average age of participants was 35.20 ± 6.87 years; 7% of the patients had side effects, none of which was considered severe. Of the patients, 66.7% responded to dimethyl sulfoxide (DMSO) and 33.3% did not respond to treatment.
Conclusion: With a 66.7% response rate, dimethyl sulfoxide (DMSO) can be considered as a potential treatment in patients with macular amyloidosis, either as a first-line therapy or in refractory cases.
References
Nilforoushzadeh MA, Zolghadr S, Heidari-Kharaji M, Alavi S, Mahmoudbeyk M. A comparative study of the efficacy of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy alone and in combination with erbium:YAG laser therapy: tracing and objective measurement of melanin index in macular amyloidosis. Lasers Med Sci. 2020;35(5):1171-1177. DOI:10.1007/s10103-020-02954-y
Weidner T, Illing T, Elsner P. Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol. 2017;18(5):629-642. DOI:10.1007/s40257-017-0278-9
Sobhi RM, Sharaoui I, El Nabarawy EA, El Nemr Esmail RS, Hegazy RA, Aref DHF. Comparative study of fractional CO₂ laser and fractional CO₂ laser-assisted drug delivery of topical steroid and topical vitamin C in macular amyloidosis. Lasers Med Sci. 2018;33(4):909-916. DOI:10.1007/s10103-018-2457-1
Verheyden M, Gupta M. Macular amyloidosis. 2020.
Piccolo V, Corneli P, Del Rosario Ossola M, et al. Macular amyloidosis and seronegative spondyloarthritis: Causal or casual association? Australas J Dermatol. 2019 Aug;60(3):e248-e249. DOI: 10.1111/ajd.13017. Epub 2019 Mar 13. PMID: 30868580.
Sonthalia S, Agrawal M, Sehgal VN. Dermoscopy of macular amyloidosis. Indian Dermatol Online J. 2021;12(1):203-205. DOI:10.4103/idoj.IDOJ_507_19
Yaman B, Kumbaracı BS, Gómez González CA, Akalın T, Şen S. C4d as a practical marker for cutaneous amyloidosis. Am J Dermatopathol. 2022;44(1):28-32. DOI:10.1097/DAD.0000000000002057
Gakkhar A, Mehendale AM, Mehendale S. An interesting case of macular amyloidosis with no significant etiology. Cureus. 2024;16(3):e56248. DOI:10.7759/cureus.56248
Ozkaya-Bayazit E, Baykal C, Kavak A. Local DMSO treatment of macular and papular amyloidosis. Hautarzt. 1997;48(1):31-37. DOI:10.1007/s001050050543
Ozkaya-Bayazit E, Kavak A, Güngör H, Ozarmagan G. Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis. Int J Dermatol. 1998;37(12):949-954. DOI:10.1046/j.1365-4362.1998.00600.x
Bandhlish A, Aggarwal A, Koranne RV. A clinico-epidemiological study of macular amyloidosis from north India. Indian J Dermatol. 2012;57(4):269-274. DOI:10.4103/0019-5154.97662
Abtahi-Naeini B, Hemati E, Faghihi G, et al. Efficacy of topical gabapentin in women with primary macular amyloidosis: a side-by-side triple-blinded randomized clinical trial. J Cosmet Dermatol. 2024;23(5):1677-1684. DOI:10.1111/jocd.16180
Rinaldi G. The itch-scratch cycle: a review of the mechanisms. Dermatol Pract Concept. 2019;9(2):90-97. DOI:10.5826/dpc.0902a03
Muir M. DMSO. Altern Complement Ther. 1996;2(4):230-235. DOI:10.1089/act.1996.2.230
Iqbal T, Kapadia N, Ather S, et al. Efficacy of topical DMSO in macular amyloidosis. J Pak Assoc Dermatol. 2017;42:43-47.
Jakhar N, Dabla K. A comparative study of the efficacy of topical steroid vs topical dimethylsulfoxide 70% in treatment of cutaneous macular amyloidosis. Int J Sci Res. 2021:48-50. DOI:10.36106/ijsr/6130085
Krishna A, Nath B, Dhir GG, et al. Study on epidemiology of cutaneous amyloidosis in northern India and effectiveness of dimethylsulphoxide in cutaneous amyloidosis. Indian Dermatol Online J. 2012;3(3):182-186. DOI:10.4103/2229-5178.101814
Saki N, Ahramiyanpour N, Heiran A, Alipour S, Parvizi MM. Efficacy of topical dimethyl sulfoxide (DMSO) 50% solution vs tretinoin 0.5% cream in treatment of patients with primary macular amyloidosis: a split-side single-blinded randomized clinical trial. Dermatol Ther. 2020;33(3):e13305. DOI:10.1111/dth.13305
Pandhi R, Kaur I, Kumar B. Lack of effect of dimethylsulphoxide in cutaneous amyloidosis. J Dermatolog Treat. 2002;13(1):11-14. DOI:10.1080/09546630252775180
Lim KB, Tan SH, Tan KT. Lack of effect of dimethyl sulphoxide (DMSO) on amyloid deposits in lichen amyloidosis. Br J Dermatol. 1988;119(3):409-410. DOI:10.1111/j.1365-2133.1988.tb03240.x
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ramina Mofarrah, Ramin Mofarrah, Masoud Farinam
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
